Literature DB >> 31168360

Treatment for Advanced Hepatocellular Carcinoma: Current Standard and the Future.

Alisa Likhitsup1, Nataliya Razumilava1, Neehar D Parikh1.   

Abstract

Entities:  

Year:  2019        PMID： 31168360      PMCID： PMC6465790          DOI： 10.1002/cld.782

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN： 2046-2484


× No keyword cloud information.
  9 in total

1.  Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center.

Authors:  Rucha M Shah; Sarah Sheikh; Jimmy Shah; Elaina Vivian; Alejandro Mejia; Islam Shahin; Parvez S Mantry
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.

Authors:  Christian S Alvarez; Jessica L Petrick; Dominick Parisi; Brian J McMahon; Barry I Graubard; Katherine A McGlynn
Journal:  Hepatology       Date:  2022-04-22       Impact factor: 17.298

3.  Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma.

Authors:  Edward Nabrinsky; Edward James
Journal:  Cureus       Date:  2020-05-16

Review 4.  Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma.

Authors:  Gabriella Aitcheson; Anjana Pillai; Bassam Dahman; Binu V John
Journal:  Curr Hepatol Rep       Date:  2021-02-01

Review 5.  Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer.

Authors:  Yara O Aghabi; Alia Yasin; James I Kennedy; Scott P Davies; Amber E Butler; Zania Stamataki
Journal:  Front Immunol       Date:  2021-04-19       Impact factor: 8.786

6.  Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy.

Authors:  Yuki Ohya; Shintaro Hayashida; Akira Tsuji; Kunitaka Kuramoto; Hidekatsu Shibata; Hiroko Setoyama; Hironori Hayashi; Kazumi Kuriwaki; Masato Sasaki; Masayoshi Iizaka; Osamu Nakahara; Yukihiro Inomata
Journal:  Surg Case Rep       Date:  2020-12-10

7.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.

Authors:  Tim F Greten; Ghassan K Abou-Alfa; Ann-Lii Cheng; Austin G Duffy; Anthony B El-Khoueiry; Richard S Finn; Peter R Galle; Lipika Goyal; Aiwu Ruth He; Ahmed O Kaseb; Robin Kate Kelley; Riccardo Lencioni; Amaia Lujambio; Donna Mabry Hrones; David J Pinato; Bruno Sangro; Roberto I Troisi; Andrea Wilson Woods; Thomas Yau; Andrew X Zhu; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 13.751

8.  A Polysaccharide From Eupolyphaga sinensis Walker With Anti-HBV Activities In Vitro and In Vivo.

Authors:  Xue Zhang; Huiling Su; Haifei Yu; Jialu Ding; Wanyu Deng; Bo Qin; Changlin Zhou; Jie Dou; Min Guo
Journal:  Front Pharmacol       Date:  2022-03-03       Impact factor: 5.810

9.  Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Gabriel Schwartz; Julianne O Darling; Malori Mindo; Lucia Damicis
Journal:  Target Oncol       Date:  2020-08       Impact factor: 4.493
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.